Back HCV Treatment

HCV Treatment

Interferon-free Daclatasvir + Asunaprevir Approved in Japan for Hepatitis C

Bristol-Myers Squibb's all-oral dual regimen of daclatasvir (Daklinza) plus asunaprevir (Sunvepra) has been approved for the treatment of chronic hepatitis C in Japan, where most people are infected with HCV genotype 1b, the company announced this week.

alt

Read more:

Survey Finds Most Primary Care Providers Unaware of New Hepatitis C Drugs

Nearly 75% of primary care physicians are unfamiliar with the most recently approved direct-acting antiviral drugs for hepatitis C, and about two-thirds are unaware of even the first-generation antivirals available since 2011, according to a recent survey by Decision Resources Group.

alt

Read more:

Boehringer Ingelheim Discontinues Faldaprevir, Halts HCV Drug Development

Boehringer Ingelheim has announced that it will discontinue development of its investigational hepatitis C virus (HCV) protease inhibitor faldaprevir, will withdraw pending approval requests, and will not proceed with further work in this area due to rapid changes in the hepatitis C treatment environment.

alt

Read more:

Studies Look at Hepatitis C Care Cascade and Healthcare Utilization

Half of people with hepatitis C in the U.S. are aware of their infection, but fewer than 10% have been successfully treated and achieved sustained virological response (SVR), according to a meta-analysis published July 2 in the open-access journal PLoS ONE. Despite these gaps in testing, care, and treatment, hepatitis C accounts for a substantial share of healthcare utilization, especially among baby boomers, a related study found.

alt

Read more:

European Regulators Give Positive Opinion on Daclatasvir for Hepatitis C

Bristol-Myers Squibb announced this week that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its hepatitis C virus (HCV) NS5A inhibitor daclatasvir, which has been given the brand name Daklinza.

alt

Read more: